...
首页> 外文期刊>Biomedicine & pharmacotherapy =: Biomedecine & pharmacotherapie >Systematic screening of protein-coding gene expression identified HMMR as a potential independent indicator of unfavorable survival in patients with papillary muscle-invasive bladder cancer
【24h】

Systematic screening of protein-coding gene expression identified HMMR as a potential independent indicator of unfavorable survival in patients with papillary muscle-invasive bladder cancer

机译:蛋白质编码基因表达的系统筛选将HMMR鉴定为乳头肌肉侵袭性膀胱癌患者不利生存的潜在独立指标

获取原文
获取原文并翻译 | 示例

摘要

Papillary and non-papillary are two histological patterns of bladder carcinogenesis and are considered as dual-track oncogenic pathways, which have different genetic alterations. The TCGA-bladder cancer (BLCA) database contains clinicopathological, genomic and survival data from over 400 muscle-invasive bladder cancer patients. In this study, using data from this database, we performed a systematic screening of gene expression to identify the protein-coding gene that might have prognostic value in papillary and non-papillary muscle-invasive bladder cancer (MIBC). The data of patients with primary MIBC in TCGA-BLCA was acquired from the UCSC Xena project (http://xena.ucsc.edu) for re-analysis. By setting vertical bar log2 fold change vertical bar >= 2 and adjusted p value<0.01 as the screening criteria, we found 751 significantly dysregulated genes, including 183 overexpressed and 568 downregulated genes. HMMR was identified as a potential prognostic marker with unique expression. Multivariate analysis showed that its expression was an independent prognostic indicator of shorter progression-free survival (PFS) (HR: 1.400, 95%CI: 1.021-1.920, p= 0.037) in the papillary subtype. ENST00000393915.8 and ENST00000358715.3, two transcripts that contain all 18 exons and encode the full length of HMMR, were significantly upregulated in cancer tissues compared with normal bladder tissues. None of the 17 CpG sites in its DNA locus was relevant to HMMR expression. 26/403 (6.5%) MIBC cases had HMMR gene-level amplification, which was associated with upregulated HMMR expression compared with the copy-neutral and deletion groups. Gene set enrichment analysis (GSEA) in papillary MIBC found that the high HMMR expression group was associated with upregulated genes enriched in multiple gene sets with well-established role in BC development, including G2M checkpoint, E2 F Targets, Myc Targets V1, Myc Targets V2 and Glycolysis. Based on these findings, we infer that HMMR expression might be a specific prognostic marker in terms of PFS in papillary MIBC. DNA amplification might be an important mechanism of its elevation.
机译:乳头状和非乳头状是两种膀胱致癌物的组织学模式,被认为是双轨致癌途径,具有不同的遗传改变。 TCGA-膀胱癌(BLCA)数据库含有来自400多个肌肉侵入性膀胱癌患者的临床病理学,基因组和生存数据。在本研究中,使用来自该数据库的数据,我们对基因表达进行了系统筛选,以鉴定可能对乳头状和非乳头肌肉侵入性膀胱癌(MIBC)具有预后价值的蛋白质编码基因。从UCSC Xena项目(http://xena.ucsc.edu)获得了TCGA-BLCA中初级MIBC患者的数据进行重新分析。通过设定垂直杆LOG2折叠变化垂直条> = 2并调整P值<0.01作为筛选标准,我们发现751显着失调的基因,包括183个过表达和568个下调基因。将HMMR鉴定为具有独特表达的潜在预后标志物。多变量分析表明,其表达是乳头状亚型中较短的无进展存活(PFS)(HR:1.400,95%Ci:1.021-1.920,P = 0.037)的独立预后指标。与正常膀胱组织相比,enst00000393915.8和enst00000358715.3和enst00000358715.3和含有所有18个外显子的转录物并编码全长HMMR,在癌症组织中显着上调。其DNA基因座中的17个CPG位点中没有任何与HMMR表达相关。 26/403(6.5%)MIBC病例具有HMMR基因水平扩增,与复制中性和缺失基团相比,与上调的HMMR表达相关。基因设定富集分析(GSEA)在乳头状MIBC中发现,高HMMR表达组与富含多种基因组中富集的上调基因相关的,在BC发育中具有良好的作用,包括G2M检查点,E2F靶标,MYC靶标V1,MYC靶标v2和糖酵解。基于这些发现,我们推出HMMR表达可能是乳头状MIBC中PFS的特异性预后标志物。 DNA扩增可能是其升高的重要机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号